Introduction {#section5-1120672118776146}
============

Radiation has increasingly replaced enucleation as an eye and vision-sparing alternative treatment for uveal melanoma. Five-year mean local control rates of up to 97% have been reported.^[@bibr1-1120672118776146]^ Though tumor size is the most well validated predictor of metastatic disease, the importance of initial local control cannot be understated.^[@bibr2-1120672118776146],[@bibr3-1120672118776146]^ In 2016, a multicenter, international data-sharing study involving 3217 patients reported significantly increased risk (6.3 hazard ratio) of metastasis if their initial uveal melanoma treatment fails.^[@bibr3-1120672118776146],[@bibr4-1120672118776146]^

Death typically follows metastasis, because there exists no curative treatment for metastatic uveal melanoma. In that local tumor recurrence has been proven to be associated with a significantly higher risk of systemic metastasis,^[@bibr4-1120672118776146]^ definitive local control (to prevent recurrence-related added metastatic risk) is currently the best way to "treat" metastatic uveal melanoma.^[@bibr3-1120672118776146],[@bibr4-1120672118776146]^

That said, the best way to make plaque radiation therapy effective is to follow consensus guidelines for medical physics measurements and clinical application.^[@bibr5-1120672118776146],[@bibr6-1120672118776146]^ Both the American Association of Physicists in Medicine (AAPM) and the American Brachytherapy Society (ABS) have sponsored multicenter, international efforts to define quality assurance, medical physics practices, and consensus guidelines. The ABS standards were created by 47 eye cancer specialists from 10 countries.^[@bibr6-1120672118776146]^

In 1990, P.T.F. initiated the first preclinical and clinical studies using ^103^Pd ophthalmic plaques for treatment of choroidal melanomas.^[@bibr7-1120672118776146],[@bibr8-1120672118776146]^ Since that time, multiple comparative dosimetry studies (including those of the AAPM TG-129) have demonstrated that in comparison to iodine-125 (^125^I), ^103^Pd photons are more rapidly absorbed within uveal melanomas, while less radiation reaches most normal ocular structures.^[@bibr5-1120672118776146],[@bibr9-1120672118776146],[@bibr10-1120672118776146]^ These attributes, coupled with careful ^103^Pd plaque-size selection (2- to 3-mm safety margins) and precise episcleral placement, has yielded some of the highest reported rates of local control associated with low rates of metastatic melanoma.^[@bibr11-1120672118776146],[@bibr12-1120672118776146]^

Once irradiated, eye cancer specialists are tasked with monitoring the tumor for regression and recurrence. Prior descriptions of uveal melanoma regression have largely concentrated on tumor-size (typically height) following brachytherapy with cobalt (^60^Co), iodine (^125^I) and ruthenium (^106^Ru) plaques, charged particles, and gamma knife.^[@bibr13-1120672118776146][@bibr14-1120672118776146][@bibr15-1120672118776146][@bibr16-1120672118776146][@bibr17-1120672118776146][@bibr18-1120672118776146][@bibr19-1120672118776146][@bibr20-1120672118776146][@bibr21-1120672118776146][@bibr22-1120672118776146][@bibr23-1120672118776146]--[@bibr24-1120672118776146]^ However, in 1982, Wilkes and Gragoudas^[@bibr25-1120672118776146]^ examined choroidal melanoma regression after proton beam irradiation, where they considered tumor thickness, pigmentation, vascularity, and subretinal fluid (SRF). Most recently, our group described regression patterns of iris melanoma following ^103^Pd plaque.^[@bibr26-1120672118776146]^ Therein, we noted that tumor vascularity, pigmentation, and thickness were the most important parameters when looking for regression.

In this era of a shifting paradigm toward eye and vision-sparing radiation, it is important to know which tumor characteristics are associated with local control. Herein, we describe the clinical features of regressing choroidal melanomas seen after ^103^Pd plaque brachytherapy.

Methods {#section6-1120672118776146}
=======

This study adhered to the tenets of the Declaration of Helsinki and the Health Insurance Portability and Accountability Act of 1996. We obtained approval from The New York Eye Cancer Center Internal Review Board to perform a retrospective chart review of 170 consecutive patients who met our inclusion criteria and had undergone ophthalmic plaque brachytherapy for choroidal melanoma between 2001 and 2012.

To provide a long-term perspective, no patients treated after 2012 were included in this study. Specific inclusion criteria were patients with at least 1-year follow-up, tumors not involving ciliary body, tumors in which location allowed observation, eyes in which media permitted adequate fundus photography, optical coherence tomography (OCT), fundus auto fluorescence (FAF), ultrasonography, and fluorescein angiography (FA).

Ophthalmic examinations were inclusive of but not limited to history, Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, pupillary reactions, ocular motility, intraocular pressure, anterior segment, and fundus examination. Features recorded at presentation included tumor pigmentation (melanotic, amelanotic, or variable), tumor epicenter quadrant, and tumor location (posterior, equatorial, or anterior).

Fundus photography was used to determine the presence of orange pigment lipofuscin (OP) and drusenoid retinal pigment epithelial detachments. FA was used to evaluate tumor intrinsic vascularity as well as SRF. OCT was most sensitive for the presence of SRF as was FAF for OP. Ultrasonography was primarily used to determine tumor configuration (dome or mushroom-shaped), internal tumor reflectivity (low, moderate, or high), tumor basal dimensions, and tumor thickness.

Initial American Joint Committee on Cancer (AJCC) staging involved whole-body positron emission tomography-computed tomography (PET-CT).^[@bibr27-1120672118776146]^ Post-treatment surveillance involved abdominal radiographic imaging every 6 months for the first 5 years and then every year thereafter. Based on the American College of Radiology Appropriateness Criteria for hepatic metastasis, the order of sensitivity was contrast-enhanced magnetic resonance imaging, computed tomography, and lastly ultrasound imaging.^[@bibr28-1120672118776146]^

For this study, local recurrence was defined as ⩾0.5 mm of apical tumor growth (by ultrasonography) or ⩾1 mm of vascularized marginal growth (by comparative fundus photography and FA). Hemorrhagic or exudative tumor enlargement was observed for regression prior to being considered growth.

Palladium-103 plaque radiation therapy {#section7-1120672118776146}
--------------------------------------

Comparative preoperative dosimetry (^125^I vs^103^Pd seeds in gold ophthalmic plaques) were performed for each patient in this series. Plaque parameters included plaque size, type of plaque, apical tumor dose, and hours of irradiation. Critical ocular structures were defined as the tumor, subjacent sclera, lens, fovea, and central optic disc. Calculations of dose to opposite eye wall most closely represented organ dose. This analysis resulted in the use of ^103^Pd in every case.^[@bibr5-1120672118776146],[@bibr10-1120672118776146]^

In this series, plaque treatments were consistent with the 2014 multicenter international ABS consensus guidelines for plaque brachytherapy of uveal melanoma. Therefore, surgery comprised tumor localization and plaque insertion, including scleral trans-illumination and intraoperative ultrasound to define tumor margins.^[@bibr29-1120672118776146]^ Each plaque was constructed and placed to cover the entire tumor plus a 2- to 3-mm tumor-free safety margin.^[@bibr5-1120672118776146],[@bibr6-1120672118776146],[@bibr30-1120672118776146]^ All patients received continuous radiation for 5--7 days.^[@bibr6-1120672118776146]^

The mean tumor apex palladium-103 radiation dose was a mean 79.5 Gray (Gy) (median 80 Gy; range 5.9--99.8 Gy). The mean plaque size was 15 mm (median 16 mm; range 10--22 mm; [Table 1](#table1-1120672118776146){ref-type="table"}).

###### 

Dosimetry and plaque treatment parameters.

![](10.1177_1120672118776146-table1)

  Variable                                         Value
  ----------------------------------- ------------ -------
  Plaque size (mm), no. (%)           10           4 (2)
  12                                  17 (10)      
  14                                  57 (34)      
  16                                  48 (28)      
  18                                  25 (15)      
  20                                  12 (7)       
  22                                  7 (4)        
  ^103^Pd seeds, no.                  Median       13
  Mean                                15           
  Range                               5--30        
  Radiation dose to tumor apex (Gy)   Median       80
  Mean                                79.5         
  Range                               5.9--99.8    
  Dose to lens (Gy)                   Median       6.5
  Mean                                11.2         
  Range                               0.9--100.3   
  Dose to fovea (Gy)                  Median       33.8
  Mean                                53.9         
  Range                               2.6--291.9   
  Dose to optic nerve (Gy)            Median       32.4
  Mean                                47.2         
  Range                               3.6--257.3   
  Duration of treatment (hours)       Median       166
  Mean                                164.1        
  Range                               118--172     

Gray (Gy) = 100 cGy.

Follow-up {#section8-1120672118776146}
---------

As possible, posttreatment fundus photography, ultrasonography, OCT, and FAF were obtained every 3--4 months after brachytherapy. FA was typically performed every 6 months to monitor changes in tumor vascularity, radiation retinopathy, and optic neuropathy. Ultrasound-imaging was used to measure the tumor and monitor for extra scleral extension. At each visit, these test results were compared with the patient's prior test examinations.

Results {#section9-1120672118776146}
=======

The mean age of the patients was 61.3 years (median 63 years; range 22--86 years). The mean follow-up duration was 71 months (median 69.5 months; range 12--201 months). The mean initial largest basal tumor dimension was 11 mm (median 10.2 mm; range 4--19.4 mm). According to the 8th edition of the American Joint Committee on Cancer staging system for uveal melanoma, there were 86-T1, 59-T2, 21-T3, and 4-T4 sized tumors ([Table 2](#table2-1120672118776146){ref-type="table"}).^[@bibr31-1120672118776146]^

###### 

Patient demographic data and pretreatment tumor classifications.

![](10.1177_1120672118776146-table2)

  Features                                                              Categories       No.    \%
  --------------------------------------------------------------------- ---------------- ------ ----
  Race                                                                  White            161    95
  Hispanic                                                              5                3      
  Asian                                                                 3                2      
  Gender                                                                Male             91     54
  Female                                                                79               46     
  Eye                                                                   Right            75     44
  Left                                                                  95               56     
  Associated comorbidities                                              Hypertension     64     38
  Diabetes                                                              19               11     
  Other cancers                                                         24               14     
  Tumor epicenter quadrant                                              Superotemporal   57     34
  Inferotemporal                                                        52               30.5   
  Superonasal                                                           24               14     
  Inferonasal                                                           32               19     
  Foveal                                                                4                2      
  Disc                                                                  1                0.5    
  Tumor location                                                        Posterior        129    76
  Equatorial                                                            24               14     
  Anterior                                                              17               10     
  AJCC staging^[a](#table-fn2-1120672118776146){ref-type="table-fn"}^   T1               86     51
  T2                                                                    59               35     
  T3                                                                    21               12     
  T4                                                                    4                2      

According to American Joint Committee on Cancer (AJCC) cancer staging manual, eighth edition.^[@bibr31-1120672118776146]^

Data were available from all 170 patients at 1 year, 136 patients at 3 years, 101 patients at 5 years, and 22 patients at 10 years of follow-up. Data were analyzed for regression patterns with respect to changes in tumor thickness, pigmentation, and vascularity changes in ultrasonography and OCT features at 1-, 3-, 5-, and 10-year follow-up ([Table 3](#table3-1120672118776146){ref-type="table"}).

###### 

Regression pattern analysis at 1, 3, 5, and 10 years.

![](10.1177_1120672118776146-table3)

  Feature                          Before surgery (*n* = 170)   1 year (*n* = 170)   3 years (*n* = 136)   5 years (*n* = 101)   10 years (*n* = 22)   Last follow-up (mean 6 years; *n* = 166)
  -------------------------------- ---------------------------- -------------------- --------------------- --------------------- --------------------- ------------------------------------------
  Mean tumor thickness (mm)        3.9                          2.4                  1.5                   1.4                   0.7                   1.7
  Pigmentation, no. (%)            170 (100)                    *n* = 170            *n* = 136             *n* = 101             *n* = 22              *n* = 166
  Increased                                                     123 (73)             84 (62)               62 (61)               11 (50)               106 (64)
  Decreased                                                     16 (9)               28 (20)               20 (20)               6 (27)                30 (18)
  Persistent                                                    31 (18)              24 (18)               19 (19)               5 (23)                30 (18)
  Orange pigment, no. (%)          136 (80)                     *n* = 170            *n* = 136             *n* = 101             *n* = 22              *n* = 166
  Present                                                       144 (85)             39 (29)               14 (14)               2 (9)                 37 (22)
  Absent                                                        26 (15)              97 (71)               87 (86)               20 (91)               129 (78)
  Subretinal fluid, no. (%)        58 (34)                      *n* = 170            *n* = 136             *n* = 101             *n* = 22              *n* = 166
  Absent                                                        116 (68)             112 (82)              83 (82)               21 (95)               117 (70)
  Persistent                                                    54 (32)              24 (18)               18 (18)               1 (5)                 49 (30)
  Intrinsic vascularity, no. (%)   120 (70)                     *n* = 120            *n* = 86              *n* = 34              *n* = 10              *n* = 120
  Resolved                                                      20 (17)              29 (34)               25 (74)               10 (100)              108 (90)
  Persistent                                                    100 (83)             57 (66)               9 (26)                0 (0)                 12 (10)
  Internal reflectivity, no. (%)   170 (100)                    *n* = 170            *n* = 136             *n* = 101             *n* = 22              *n* = 166
  Low                                                           21 (12)              7 (5)                 0 (0)                 0 (0)                 6 (4)
  Moderate                                                      63 (37)              39 (29)               30 (30)               0 (0)                 48 (29)
  High                                                          86 (51)              90 (66)               71 (70)               22 (100)              112 (67)

Comparison of regression characteristics before and after treatment {#section10-1120672118776146}
-------------------------------------------------------------------

### Change in tumor size on ultrasound {#section11-1120672118776146}

The mean initial tumor thickness was 3.9 mm (median 2.8 mm; range 2--11.3 mm) which reduced to 1.7 mm (median 1.2 mm; range 0--7.1 mm) at last follow-up. Radiation induced a mean 44% reduction in thickness in this series. All tumors showed reduction in tumor thickness except the one with recurrence.

Ultrasonographic internal reflectivity prior to radiation revealed that 13% (*n* = 22/170) tumors with low, 75% (*n* = 127/170) moderate, and 12% (*n* = 21/170) were highly reflective. Of the tumors with low to moderate internal reflectivity, 61% (*n* = 91/149) demonstrated an increase in internal reflectivity ([Table 4](#table4-1120672118776146){ref-type="table"}). Tumors that started with high internal reflectivity remained highly reflective.

###### 

Comparison of regression characteristics before and after treatment.

![](10.1177_1120672118776146-table4)

                          Features                                           Characteristics   Before Rx (*n* = 170)   After Rx (*n* = 166)         
  ----------------------- -------------------------------------------------- ----------------- ----------------------- ---------------------- ----- ----
  Clinically              Pigmentation                                       Pigmented         86                      51                     106   64
  Amelanotic              17                                                 10                30                      18                           
  Variable                67                                                 39                30                      18                           
  Orange pigment          Granular                                           85                50                      12                     7     
  Gross                   51                                                 30                25                      15                           
  Absent                  34                                                 20                129                     78                           
  FAF                     Orange pigment                                     Granular          42                      25                     8     5
  Gross                   20                                                 12                17                      10                           
  Absent                  29                                                 17                47                      28                           
  N/A                     79                                                 46                94                      57                           
  OCT                     Drusenoid retinal pigment epithelial detachments   Present           30                      18                     0     0
  Absent                  140                                                82                166                     100                          
  Subretinal fluid        Apical                                             26                16                      9                      6     
  Dependent               18                                                 10                0                       0                            
  Foveal                  14                                                 8                 40                      24                           
  Absent                  112                                                66                117                     70                           
  FFA                     Intrinsic vascularity                              Microaneurysms    100                     59                     12    7
  Vessels                 20                                                 12                0                       0                            
  Absent                  50                                                 29                154                     93                           
  USG                     Tumor configuration                                Dome              148                     87                     86    52
  Mushroom-shaped         22                                                 13                19                      11                           
  Flat                    0                                                  0                 61                      37                           
  Internal reflectivity   Low                                                22                13                      6                      4     
  Moderate                127                                                75                48                      29                           
  High                    21                                                 12                112                     67                           

FAF: fundus auto fluorescence; OCT: optical coherence tomography; FFA: fundus fluorescein angiography; USG: ultrasonography.

Ultrasonographic shape prior to radiation revealed 87% (*n* = 148/170) to be dome-shaped and 13% (*n* = 22/170) to form a mushroom shape. Of the dome-shaped tumors, 58% (*n* = 86/148) remained dome-shaped and 41% (*n* = 61/148) became flat. Of the mushroom shaped tumors, 86% (*n* = 19/22) maintained their mushroom shape with reduced thickness. No patient had evidence of extra scleral extension.

### Change in tumor color {#section12-1120672118776146}

Fundus photography revealed that 51% (*n* = 86/170) of tumors were pigmented, 39% (*n* = 67/170) were variably pigmented, and 10% (*n* = 17/170) were amelanotic. At the last follow-up, tumor pigmentation was found to be increased in 64% (*n* = 106/166), decreased in 18% (*n* = 30/166), and unchanged in 18% (*n* = 30/166; [Figure 1](#fig1-1120672118776146){ref-type="fig"}).

![Fundus photographs of a T2-sized choroidal melanoma (top left) before surgery and (bottom left) 8 years after brachytherapy. Note the change in pigmentation to bluish black, resolution of DRPEDs, and increase in orange pigment lipofuscin. Fundus photographs of a mushroom-shaped choroidal melanoma (top right) before surgery and (bottom right) 3 years after brachytherapy. Note the resolution of intrinsic tumor vascularity.](10.1177_1120672118776146-fig1){#fig1-1120672118776146}

At last follow-up, subgroup analysis of the 129 tumors located posterior to the equator, 61% (*n* = 79/129) became more pigmented, 22% (*n* = 29/129) variably pigmented, and 13% (*n* = 17/129) became atrophic scars. Of tumors centered at the equator, 91% (*n* = 22/24) became more pigmented. Of interest, 76% (*n* = 13/18) of the anteriorly located tumors became atrophic scars.

### Change in OP {#section13-1120672118776146}

Clinically: at presentation, 50% (*n* = 85/170) tumors had granular and 30% (*n* = 51/170) had gross OP. After 1 year of treatment, OP was present in 85% (*n* = 144/170). After 3 years of treatment, OP diminished to 29% (*n* = 39/136) and almost disappeared to 9% (*n* = 2/22) after 10 years. It is important to note that 14% (*n* = 12/85) had persistent granular and 49% (*n* = 25/51) had persistent gross OP at the last follow-up ([Figure 1](#fig1-1120672118776146){ref-type="fig"}).

Imaging observations: on fundus autofluorescence, 25% (*n* = 42/170) tumors had granular and 12% (*n* = 20/170) had gross orange pigmentation. At the last follow-up, 19% (*n* = 8/42) had persistent granular and 85% (*n* = 17/20) had persistent gross OP. It is important to note that the patient who developed recurrence showed increase in orange pigmentation on autoflorescence at the site of recurrence.

### Changes in OCT {#section14-1120672118776146}

Subretinal fluid (SRF) was present in 34% (*n* = 58/170) eyes, out of which, 45% (*n* = 26/58) had apical, 31% (*n* = 18/58) had dependent, and 24% (*n* = 14/58) had subfoveal fluid. After 18 months of treatment, resolution of SRF began and only 15% (*n* = 9/58) patients had persistent SRF due to tumor at last follow-up. The dependent SRF resolved in all patients and 24% (*n* = 40/166) patients developing radiation maculopathy/retinopathy ended up with persistent intraretinal fluid in the macular retina.

Drusenoid retinal pigment epithelial detachments (DRPED) were present on 18% (*n* = 30/170) of tumors prior to radiation. All (*n* = 30/30) of these tumors showed resolution of DRPED at last follow-up ([Figure 1](#fig1-1120672118776146){ref-type="fig"}).

### Changes on FA {#section15-1120672118776146}

On FA, dot micro-aneurysms were noted in 59% (*n* = 100/170) and intrinsic tumor vessels in 12% (*n* = 20/170) tumors prior to radiation. At last follow-up, 88% (*n* = 88/100) of micro-aneurysms had resolved. Similarly, 100% (*n* = 20/20) of intrinsic tumor blood vessels had resolved.

### Visual acuity {#section16-1120672118776146}

Pretreatment visual acuities were a median of 20/25 (mean, 20/32; range, 20/16 to counting fingers). They decreased to a median of 20/32 (mean, 20/63; range, 20/16 to no light perception) at a mean 71 months follow-up ([Table 5](#table5-1120672118776146){ref-type="table"}).

###### 

Complications and visual, ocular, and systemic outcomes at last follow-up.

![](10.1177_1120672118776146-table5)

                                                                    Variable                                                                                       No. (*n* = 170)   \%
  ----------------------------------------------------------------- ------------------------------------------------------------------------ --------------------- ----------------- ----
  Complications                                                     Dry eye                                                                                        0                 0
  Scleromalacia                                                                                                                              0                     0                 
  Cataract^[a](#table-fn5-1120672118776146){ref-type="table-fn"}^                                                                            15                    9                 
  Glaucoma (including NVG)                                                                                                                   10                    6                 
  Radiation retinopathy                                                                                                                      82                    48                
  Radiation maculopathy                                                                                                                      26                    15                
  Radiation optic neuropathy                                                                                                                 24                    14                
  Outcomes                                                          Vision outcomes^[b](#table-fn6-1120672118776146){ref-type="table-fn"}^   Good (20/16--20/40)   95                56
  Intermediate (20/50--20/200)                                      39                                                                       23                                      
  Poor (\<20/200)                                                   36                                                                       21                                      
  Ocular outcomes                                                   Tumor recurrence                                                         1                     0.5               
  Enucleation                                                       4                                                                        2                                       
  Eye salvage                                                       166                                                                      98                                      
  Systemic outcomes                                                 Distant metastases                                                       10                    6                 
  No distant metastases                                             160                                                                      94                                      

NVG: neovascular glaucoma.

New onset and worsening of preexisting disease.

Final best-corrected visual acuity.

Subgroup analysis revealed that out of 80% (*n* = 136/170) who had a baseline acuity of 20/16--20/40, 66% (*n* = 89/136) retained 20/16--20/40 at last follow-up. Reductions in visual acuity in 18 patients was attributed to radiation induced retinopathy and maculopathy.

Subgroup analysis of the 14% (*n* = 24/170) who had a baseline acuity of 20/50--20/200 showed that 25% (*n* = 6/24) improved to 20/16--20/40, and 42% (*n* = 10/24) retained 20/50--20/200 at last follow-up.

Subgroup analysis of the 6% (*n* = 10/170) who had a baseline acuity of \<20/200, 10% (*n* = 1/10) improved to 20/50--20/200, and 90% (n = 9/10) continued with \<20/200 at last follow-up This finding was mainly attributed to tumor location beneath the fovea or involving the optic disc.

### Cataract and radiation vasculopathy {#section17-1120672118776146}

Of the patients who were phakic at the time of treatment 10% (*n* = 15/151) developed radiation-induced cataract. These cataracts were considered as acceptable and safely treatable consequences related to plaque brachytherapy.

Radiation retinopathy alone was the most common cause of treatment-related vision loss present in 48% (*n* = 82/170) patients. All patients were examined for the presence of radiation maculopathy and radiation optic neuropathy (RON) and were staged according to the Ophthalmic Radiation Oculopathy for Vision Prognosis Classification.^[@bibr32-1120672118776146]^ No radiation oculopathy (Stage 0) was noted in 41% (*n* = 69/170) eyes at last follow-up. Stages 1--3 retinopathy was noted in 44% (*n* = 75/170). Stage 4 retinopathy primarily characterized by vitreous hemorrhage and RON was noted in 15% (*n* = 26/170). Initiated at the first clinical sign of neuropathy or maculopathy, 96 patients have been treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy to suppress radiation-induced retinopathy or/and optic neuropathy.^[@bibr33-1120672118776146][@bibr34-1120672118776146]--[@bibr35-1120672118776146]^

#### Unusual regression patterns {#section18-1120672118776146}

Seven irradiated melanomas were found to evolve into peculiar donut configuration (atrophy surrounded by pigmentation surrounded by atrophy) at last follow-up. All these tumors shared the common features of posterior location and an overlying fibrotic component prior to radiation therapy.

Also, melanomas with a mushroom-shape regressed such that the main body of the tumor shrunk, the mushroom configuration persisted, though to a darker color.

#### Histopathology {#section19-1120672118776146}

On histopathological evaluation of the four enucleated eyes, 75% (*n* = 3/4) had 1--2 mitotic figures/40 high-power fields showing that cells can enter mitosis even after irradiation. As radiation induces programmed DNA-damage-mediated cell death, the cytotoxic effect becomes histopathologically apparent only when cells enter mitosis over subsequent years.^[@bibr36-1120672118776146]^ In addition, no radiation-treated choroidal melanoma was reported to have vascular loops. Thus, these four cases offer histopathologic corroboration of our angiographic observations that resolution of vascularity was a consistent finding associated with tumor regression.

### Tumor resolution and metastasis {#section20-1120672118776146}

In this series, local tumor control (no recurrence) was achieved in 99.5% (*n* = 169/170) patients. Eye retention was seen in 98% (*n* = 166/170) patients. Four (2%) patients (*n* = 4/170) required secondary enucleation for neovascular glaucoma. Ten (6%) patients (*n* = 10/170) developed metastasis.

Discussion {#section21-1120672118776146}
==========

In this study, side-by-side comparison of fundus photographs, OCT, FA, and ultrasonography from each follow-up visit was useful for detecting changes in pigmentation, SRF, vascularity, tumor size, and reflectivity after treatment.

Ultrasonography {#section22-1120672118776146}
---------------

Radiation induced a mean 44% reduction in tumor thickness in this series. We observed that the signs of tumor regression are decreased tumor thickness along with increased internal reflectivity.

Tumor color {#section23-1120672118776146}
-----------

At last follow-up, tumor pigmentation was found to be increased in 64% (*n* = 106/166) eyes. The tumors that were pigmented at presentation typically developed a dark bluish hue. Tumors located in the posterior and equatorial fundus typically regressed with increased pigmentation, whereas the tumors located in the anterior position more commonly regressed to chorioretinal atrophy. This may be due a vaso-occlusive radiation effect on the thinner peripheral choroid.

Orange Pigment {#section24-1120672118776146}
--------------

OP has been found after damage to various other human tissues like heart, liver, colon, and testis and is considered to be a nonspecific sign of cell death.^[@bibr37-1120672118776146]^ In this study, we have noticed that OP gradually increased over the first 3 years after radiation. The clumps of gross OP consolidated and became more prominent, as if the OP revealed itself or more likely increased after treatment. Tumors that started with granular OP evolved to reveal gross OP. Then, 3 years after treatment, OP declined and almost disappeared after 5--10 years of treatment. This latter finding, and as we observed on our solitary recurrence, suggests that the presence of new OP should be considered along with other signs of recurrence.

Radiation vasculopathy {#section25-1120672118776146}
----------------------

Leakage from the tumor decreased within first 3 years as the tumor regressed. However, radiation-related exudative retinal changes started to appear between 18 and 24 months after treatment.^[@bibr35-1120672118776146]^ The most common cause of SRF at the last follow-up was radiation-related retinal vascular changes (including intraretinal fluid). intraretinal fluid. Radiation maculopathy was largely supressed with intravitreal anti-VEGF therapy.^[@bibr33-1120672118776146][@bibr34-1120672118776146]--[@bibr35-1120672118776146]^

Tumor vascularity {#section26-1120672118776146}
-----------------

Tumor vascularity reduced and typically disappeared over time. This is an "in-vivo" demonstration of radiation's vaso-occlusive effect on uveal melanoma and choroidal vasculature.^[@bibr38-1120672118776146]^ Partial reduction or complete elimination of intrinsic tumor vascularity was found to be the most consistent finding related to tumor regression. This finding suggests that the presence of new tumor vascularity suggests tumor recurrence.

In the literature review, descriptions of regression of choroidal melanoma after treatment have largely been limited to ultrasonographic tumor thickness reduction.^[@bibr13-1120672118776146][@bibr14-1120672118776146][@bibr15-1120672118776146][@bibr16-1120672118776146][@bibr17-1120672118776146][@bibr18-1120672118776146][@bibr19-1120672118776146][@bibr20-1120672118776146][@bibr21-1120672118776146][@bibr22-1120672118776146][@bibr23-1120672118776146]--[@bibr24-1120672118776146]^ Rashid et al.^[@bibr39-1120672118776146]^ reported 43% decrease in thickness and 42% decrease in cross-sectional area of tumor after ^106^Ru and ^125^I plaque brachytherapy. A recent study by Rashid et al.^[@bibr40-1120672118776146]^ also reported that initial tumor thickness was the predominant clinical predictor of regression rate of choroidal melanomas after ^106^Ru and ^125^I brachytherapy. Abramson et al.^[@bibr15-1120672118776146]^ also reported that the amount of reduction in tumor thickness after ^60^Co and ^125^I therapy was the same, irrespective of location of tumor. Salvi et al.^[@bibr41-1120672118776146]^ noted that the regression of tumor height at 3, 6, and 12 months with ^125^I did not statistically correlate with tumor location. In our study, all lesions, irrespective of location and shape, show similar amounts of reduction in tumor thickness. Using proton therapy, Wilkes and Gragoudas^[@bibr25-1120672118776146]^ noted resolution of the secondary serous retinal detachments in 100% (our study 85%) and destruction of the tumor's vasculature with elimination of leakage on FA in 66% (our study 90%). In addition, the 1982 Wilkes study could not report on newly available OCT and FAF findings and nor did they analyze radiation-related changes or vision outcomes.

With respect to local control: in a review of 100 patients treated with ^60^Co plaque, Cruess et al.^[@bibr13-1120672118776146]^ reported that there was no difference in the rate and extent of tumor regression between the patients who developed metastasis and the ones who did not. Kaiserman et al.^[@bibr42-1120672118776146]^ found that the initial tumor thickness regression rate was significantly higher in patients who developed metastasis (6% per month) compared to patients who did not (4% per month), with ^106^Ru plaque. Glynn et al.^[@bibr43-1120672118776146]^ following proton beam radiotherapy, found that tumors regressing rapidly were significantly more likely to develop metastasis within 2 years of treatment, while tumors with slow regression developed metastasis after 2 years of treatment. In our study, we found no difference in the rate of tumor regression between patients who developed metastasis and those who remained well systemically.

In terms of visual acuity: Marconi et al.^[@bibr44-1120672118776146]^ noted that after ^106^Ru plaque brachytherapy, 56% of patients had visual acuity of 20/25 initially, out of which more than half stayed with 20/40. Patel et al.^[@bibr45-1120672118776146]^ compared ^103^Pd with ^125^I and found that \>20/40 visual acuity was noted in 65% with ^103^Pd versus 30% with ^125^I. Papakostas et al.^[@bibr46-1120672118776146]^ noted visual acuity of ⩾20/200 in 8.7% patients and counting fingers in 22% patients after proton beam radiotherapy. In our study, we noted excellent median visual acuity of 20/32 with ^103^Pd plaque brachytherapy.

In that, choroidal melanomas have been reported to appear in various configurations: dome, mushroom-shaped, and irregular. They can be melanotic, amelanotic, or demonstrate variable pigmentation. They may be associated with orange pigment, vascularity, or SRF. Clearly, a single parameter of change (as measured thickness) does not comprehensively define regression of choroidal melanomas.

Advantages of our study {#section27-1120672118776146}
-----------------------

This study benefits from its long duration of follow-up, the use of a single treatment modality, and that all surgeries were performed by one, experienced surgeon (P.T.F.) who has chaired or participated in recent ABS and AAPM guideline initiatives.^[@bibr5-1120672118776146],[@bibr6-1120672118776146],[@bibr30-1120672118776146]^ With such high (99.5%) local control (at a mean duration of 71 months after ^103^Pd plaque brachytherapy), our outcomes should be considered reliable characteristics of choroidal melanoma regression.

Limitations of this study {#section28-1120672118776146}
-------------------------

This study was retrospective. Although reasonably sized compared to published reports in the literature, a large multicenter cooperative "big data" registry study would improve validation and allow for observations after alternative methods of radiation therapy.

In conclusion {#section29-1120672118776146}
-------------

Findings related to choroidal melanoma regression (after ^103^Pd plaque brachytherapy) include increased tumor pigmentation of posterior tumors, an evolution from increased to decreased OP and complete resolution of DRPED. FA and histopathology revealed resolution of intrinsic tumor vascularity, while OCT showed decreased tumor-related, exudative SRF. Finally, ultrasound imaging revealed decreased tumor thickness with a trend toward synchronous increased internal reflectivity. We hope this study serves to aid to the clinical judgment of those who treat and follow patients with choroidal melanoma.
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